跳至主要内容
临床试验/NCT02856542
NCT02856542已完成不适用

Real-life Evaluation of an Applicator, as a New Mode of Administration of Daivobet® Gel, on Adherence to Treatment and SAtisfaction of Patients With PSOriasis

LEO Pharma1 个研究点 分布在 1 个国家目标入组 1,560 人开始时间: 2016年5月23日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
LEO Pharma
入组人数
1,560
试验地点
1
主要终点
Morisky Medication Adherence Scale-8

研究概览

简要总结

This study aims to describe the patient population being treated and evaluate their treatment adherence and treatment outcomes during treatment of scalp psoriasis with Daivobet® gel Applicator for 4 weeks.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • Dermatologist or general practitioner has decided to initiate treatment with Daivobet® gel Applicator

排除标准

  • Indication not within the approved labelling in France
  • Contraindication for treatment with calcipotriol or betamethasone dipropionate
  • Informed consent to participate in the study has not been obtained

结局指标

主要结局

Morisky Medication Adherence Scale-8

时间窗: 4 weeks

Degree of adherence to prescribed treatment

次要结局

  • Patient opinion on Applicator usability(4 weeks)
  • Patient overall satisfaction(4 weeks)
  • Patient Global Impression of Improvement(4 weeks)
  • Investigator's opinion on the properties of the Applicator(Baseline)

研究者

发起方
LEO Pharma
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验